FDA Publishes Immunogenicity Guidelines For Biosimilar Insulins
Biosimilar Insulins Generally Will Not Need Comparative Clinical Immunogenicity Data
In a move that will likely be welcomed by industry, the US FDA has issued draft guidance stating that sponsors will generally not need to conduct comparative clinical immunogenicity studies in developing biosimilar/interchangeable products.
